Fresh from its takeover of Alexion, AstraZeneca has picked up a recommendation in the EU for an expansion of the label of Ultomiris, one of the main assets behind the
Bayer subsidiary BlueRock Therapeutics has been granted a fast-track review by the FDA for DA01, its stem cell-based therapy for Parkinson's disease which is currently in early-stage clinic
French drugmaker Ipsen has made another foray into the Parkinson's disease category, licensing rights to an oral dopamine D3 receptor antagonist from Sweden's IRLAB for $28 million upfront.
Bayer subsidiary BlueRock Therapeutics has dosed the first Parkinson's disease patient in a phase 1 trial of its cell-based therapy DA01, which aims to replenish the neurons lost in people
Sleep disturbances are a common feature for people with Parkinson’s disease, and a device developed to help people with insomnia is now being trialled to see if it can improve their sleep q
Canada’s Valence Discovery has joined a University of Montreal-led project to try to find new drugs to treat the involuntary movement complications that can accompany treatments for Parkins